Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci
Streptococcus pneumoniae serotype 3 remains a significant cause of morbidity and mortality worldwide, despite inclusion in the 13-valent pneumococcal conjugate vaccine (PCV13). Serotype 3 increased in carriage since the implementation of PCV13 in the USA, while invasive disease rates remain unchanged. We investigated the persistence of serotype 3 in carriage and disease, through genomic analyses of a global sample of 301 serotype 3 isolates of the Netherlands3-31 (PMEN31) clone CC180, combined with associated patient data and PCV utilization among countries of isolate collection. We assessed phenotypic variation between dominant clades in capsule charge (zeta potential), capsular polysaccharide shedding, and susceptibility to opsonophagocytic killing, which have previously been associated with carriage duration, invasiveness, and vaccine escape. We identified a recent shift in the CC180 population attributed to a lineage termed Clade II, which was estimated by Bayesian coalescent analysis to have first appeared in 1968 [95% HPD: 1939-1989] and increased in prevalence and effective population size thereafter. Clade II isolates are divergent from the pre-PCV13 serotype 3 population in non-capsular antigenic composition, competence, and antibiotic susceptibility, the last of which resulting from the acquisition of a Tn916-like conjugative transposon. Differences in recombination rates among clades correlated with variations in the ATP-binding subunit of Clp protease, as well as amino acid substitutions in the comCDE operon. Opsonophagocytic killing assays elucidated the low observed efficacy of PCV13 against serotype 3. Variation in PCV13 use among sampled countries was not independently correlated with the CC180 population shift; therefore, genotypic and phenotypic differences in protein antigens and, in particular, antibiotic resistance may have contributed to the increase of Clade II. Our analysis emphasizes the need for routine, representative sampling of isolates from disperse geographic regions, including historically under-sampled areas. We also highlight the value of genomics in resolving antigenic and epidemiological variations within a serotype, which may have implications for future vaccine development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
PLoS pathogens - 14(2018), 11 vom: 26. Nov., Seite e1007438 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azarian, Taj [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 15.02.2019 Date Revised 04.10.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1371/journal.ppat.1007438 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM291072305 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM291072305 | ||
| 003 | DE-627 | ||
| 005 | 20231225070111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.ppat.1007438 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0970.xml |
| 035 | |a (DE-627)NLM291072305 | ||
| 035 | |a (NLM)30475919 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Azarian, Taj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.02.2019 | ||
| 500 | |a Date Revised 04.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Streptococcus pneumoniae serotype 3 remains a significant cause of morbidity and mortality worldwide, despite inclusion in the 13-valent pneumococcal conjugate vaccine (PCV13). Serotype 3 increased in carriage since the implementation of PCV13 in the USA, while invasive disease rates remain unchanged. We investigated the persistence of serotype 3 in carriage and disease, through genomic analyses of a global sample of 301 serotype 3 isolates of the Netherlands3-31 (PMEN31) clone CC180, combined with associated patient data and PCV utilization among countries of isolate collection. We assessed phenotypic variation between dominant clades in capsule charge (zeta potential), capsular polysaccharide shedding, and susceptibility to opsonophagocytic killing, which have previously been associated with carriage duration, invasiveness, and vaccine escape. We identified a recent shift in the CC180 population attributed to a lineage termed Clade II, which was estimated by Bayesian coalescent analysis to have first appeared in 1968 [95% HPD: 1939-1989] and increased in prevalence and effective population size thereafter. Clade II isolates are divergent from the pre-PCV13 serotype 3 population in non-capsular antigenic composition, competence, and antibiotic susceptibility, the last of which resulting from the acquisition of a Tn916-like conjugative transposon. Differences in recombination rates among clades correlated with variations in the ATP-binding subunit of Clp protease, as well as amino acid substitutions in the comCDE operon. Opsonophagocytic killing assays elucidated the low observed efficacy of PCV13 against serotype 3. Variation in PCV13 use among sampled countries was not independently correlated with the CC180 population shift; therefore, genotypic and phenotypic differences in protein antigens and, in particular, antibiotic resistance may have contributed to the increase of Clade II. Our analysis emphasizes the need for routine, representative sampling of isolates from disperse geographic regions, including historically under-sampled areas. We also highlight the value of genomics in resolving antigenic and epidemiological variations within a serotype, which may have implications for future vaccine development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 700 | 1 | |a Mitchell, Patrick K |e verfasserin |4 aut | |
| 700 | 1 | |a Georgieva, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Claudette M |e verfasserin |4 aut | |
| 700 | 1 | |a Ghouila, Amel |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a von Gottberg, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a du Plessis, Mignon |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Kwambana-Adams, Brenda A |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Stuart C |e verfasserin |4 aut | |
| 700 | 1 | |a Everett, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Cornick, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Sadowy, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Hryniewicz, Waleria |e verfasserin |4 aut | |
| 700 | 1 | |a Skoczynska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Moïsi, Jennifer C |e verfasserin |4 aut | |
| 700 | 1 | |a McGee, Lesley |e verfasserin |4 aut | |
| 700 | 1 | |a Beall, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Metcalf, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Breiman, Robert F |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, P L |e verfasserin |4 aut | |
| 700 | 1 | |a Reid, Raymond |e verfasserin |4 aut | |
| 700 | 1 | |a O'Brien, Katherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Gladstone, Rebecca A |e verfasserin |4 aut | |
| 700 | 1 | |a Bentley, Stephen D |e verfasserin |4 aut | |
| 700 | 1 | |a Hanage, William P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLoS pathogens |d 2005 |g 14(2018), 11 vom: 26. Nov., Seite e1007438 |w (DE-627)NLM158124782 |x 1553-7374 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2018 |g number:11 |g day:26 |g month:11 |g pages:e1007438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.ppat.1007438 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2018 |e 11 |b 26 |c 11 |h e1007438 | ||